Contribution to the knowledge of sarcoma, Ann Surg, vol.14, pp.199-220, 1891. ,
The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas, Iowa Orthop J, vol.26, pp.154-158, 2006. ,
Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy, Expert Rev Vaccines, vol.14, pp.1255-1275, 2015. ,
Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors, J Urol, vol.116, pp.180-183, 1976. ,
Mechanisms of BCG immunotherapy and its outlook for bladder cancer, Nat Rev Urol, vol.15, pp.615-625, 2018. ,
URL : https://hal.archives-ouvertes.fr/pasteur-01880693
Cytokine-induced killer cells promote antitumor immunity, J Transl Med, vol.11, p.83, 2013. ,
The basic principles of chimeric antigen receptor design, Cancer Discov, vol.3, pp.388-398, 2013. ,
Cancer statistics, CA Cancer J Clin, vol.68, pp.7-30, 2018. ,
Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook, Ther Clin Risk Manag, vol.14, pp.1019-1040, 2018. ,
On the pathological relations between cancer and tuberculosis, Exp Biol Med, vol.26, pp.73-75, 1928. ,
Employment of B. C. G. especially in Intravenous Injection, Acta Med Scand, vol.90, pp.350-361, 1936. ,
,
Chemoimmune prophylaxis of superficial bladder cancer, J Urol, vol.129, pp.29-32, 1983. ,
Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer, J Urol, vol.124, pp.38-40, 1980. ,
Bladder cancer immunotherapy, J Urol, vol.128, pp.931-935, 1982. ,
URL : https://hal.archives-ouvertes.fr/pasteur-01380581
Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma, J Urol, vol.128, pp.27-30, 1982. ,
Bacillus Calmette-Guerin for superficial transitional cell carcinoma of the bladder, J Urol, vol.135, pp.261-264, 1986. ,
Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer, J Urol, vol.143, pp.502-506, 1990. ,
A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder, N Engl J Med, vol.325, pp.1205-1209, 1991. ,
An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer, Eur Urol, vol.56, pp.247-256, 2009. ,
Long-term efficacy of maintenance bacillus Calmette-Guerin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up, Eur Urol, vol.56, pp.260-265, 2009. ,
Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate-and high-risk stage Ta T1 urothelial carcinoma of the bladder, Eur Urol, vol.57, pp.766-773, 2010. ,
Intravesical bacillus Calmette-Guerin versus epirubicin for Ta and T1 bladder cancer, Cochrane Database Syst Rev, p.6885, 2011. ,
Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study, J Urol, vol.163, pp.1124-1129, 2000. ,
Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate-and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance, Eur Urol, vol.63, pp.462-472, 2013. ,
Maintenance bacillus Calmette-Guerin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence, Eur Urol, vol.64, pp.579-585, 2013. ,
From infection to immunotherapy: host immune responses to bacteria at the bladder mucosa, Mucosal Immunol, vol.6, pp.1041-1053, 2013. ,
URL : https://hal.archives-ouvertes.fr/pasteur-01385511
The mechanism of action of BCG therapy for bladder cancer -a current perspective, Nat Rev Urol, vol.11, pp.153-162, 2014. ,
Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall, J Urol, vol.144, pp.53-58, 1990. ,
Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: involvement of toll-like receptors, Infect Immun, vol.68, pp.6883-6890, 2000. ,
Enhanced antigen-presenting activity and tumour necrosis factor-alpha-independent activation of dendritic cells following treatment with Mycobacterium bovis bacillus Calmette-Guerin, Immunology, vol.97, pp.626-633, 1999. ,
A possible mechanism of intravesical BCG therapy for human bladder carcinoma: involvement of innate effector cells for the inhibition of tumor growth, Cancer Immunol Immunother, vol.58, pp.1245-1255, 2009. ,
Urine dendritic cells: a noninvasive probe for immune activity in bladder cancer?, BJU Int, vol.94, pp.1377-1383, 2004. ,
Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guerin immunotherapy, Eur Urol, vol.55, pp.1386-1396, 2009. ,
Neutrophil granulocytes are required for effective bacillus Calmette-Guerin immunotherapy of bladder cancer and orchestrate local immune responses, Cancer Res, vol.66, pp.8250-8257, 2006. ,
NK cells are essential for effective BCG immunotherapy, Int J Cancer, vol.92, pp.697-702, 2001. ,
NKG2D is a key receptor for recognition of bladder cancer cells by IL-2-activated NK cells and BCG promotes NK cell activation, Front Immunol, vol.6, p.284, 2015. ,
Significance of target cell infection and natural killer cells in the anti-tumor effects of bacillus Calmette-Guerin in murine bladder cancer, Oncol Rep, vol.17, pp.1469-1474, 2007. ,
Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation, J Urol, vol.172, pp.1490-1495, 2004. ,
Inhibition of murine bladder tumor growth by bacille Calmette-Guerin: lack of a role of natural killer cells, Clin Immunol Immunopathol, vol.41, pp.108-115, 1986. ,
Cellular cytotoxicity of human natural killer cells and lymphokine-activated killer cells against bladder carcinoma cell lines, Immunol Lett, vol.27, pp.191-197, 1991. ,
Intravesical Evans Strain BCG therapy -quantitative immunohistochemical analysis of the immune-response within the bladder wall, J Urol, vol.147, pp.1636-1642, 1992. ,
Evaluation of cellular tumour rejection mechanisms in the peritumoral bladder wall after bacillus Calmette-Guerin treatment, BJU Int, vol.88, pp.602-610, 2001. ,
Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation, J Urol, vol.181, pp.1894-1900, 2009. ,
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human bladder cancer, Cancer Immun, vol.7, p.10, 2007. ,
HLA-DR expression by high grade superficial bladder cancer treated with BCG, Br J Urol, vol.63, pp.264-269, 1989. ,
Class I and class II HLA antigen expression by transitional cell carcinoma of the bladder: correlation with T-cell infiltration and BCG treatment, J Urol, vol.141, pp.1449-1453, 1989. ,
Markers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic review, Eur Urol, vol.61, pp.128-145, 2012. ,
Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer, J Urol, vol.167, pp.364-367, 2002. ,
Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect, Cytokine, vol.21, pp.17-26, 2003. ,
T-cell subsets required for intravesical BCG immunotherapy for bladder cancer, J Urol, vol.150, pp.1018-1023, 1993. ,
Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical bacillus Calmette-Guerin therapy in bladder cancer, Oncotarget, vol.7, pp.39916-39930, 2016. ,
Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer, Sci Transl Med, vol.4, pp.137-172, 2012. ,
URL : https://hal.archives-ouvertes.fr/pasteur-01402032
Systemic immunotherapy of non-muscle invasive mouse bladder cancer with avelumab, an anti-PD-L1 immune checkpoint inhibitor, Cancer Immunol Res, vol.4, pp.452-462, 2016. ,
Systemic immune response after intravesical instillation of bacille Calmette-Guerin (BCG) for superficial bladder cancer, Clin Exp Immunol, vol.115, pp.131-135, 1999. ,
Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guerin, J Urol, vol.135, pp.268-271, 1986. ,
Re: purified protein derivative skin test reactions are associated with clinical outcomes of patients with nonmuscle invasive bladder cancer treated with induction bacillus Calmette-Guerin therapy, Urol Oncol, vol.37, pp.346-347, 2019. ,
Purified protein derivative skin test reactions are associated with clinical outcomes of patients with nonmuscle invasive bladder cancer treated with induction bacillus Calmette-Guerin therapy, Urol Oncol, vol.36, pp.77-92, 2018. ,
Purified protein derivative skin test prior to bacillus Calmette-Guerin therapy may have therapeutic impact in patients with nonmuscle invasive bladder cancer, J Urol, vol.199, pp.1446-1451, 2018. ,
Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer, Med Oncol, vol.34, p.170, 2017. ,
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer, Nature, vol.515, pp.558-562, 2014. ,
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, Lancet, vol.387, pp.1909-1920, 2016. ,
Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study, Ann Oncol, vol.28, pp.3044-3050, 2017. ,
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial, Lancet, vol.389, pp.67-76, 2017. ,
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial, Lancet, vol.391, pp.748-757, 2018. ,
Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer, J Clin Oncol, vol.34, pp.3119-3125, 2016. ,
Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study, JAMA Oncol, vol.3, p.172411, 2017. ,
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial, Lancet Oncol, vol.18, pp.587-598, 2017. ,
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial, Lancet Oncol, vol.19, pp.51-64, 2018. ,
Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study, J Clin Oncol, vol.35, pp.2117-2124, 2017. ,
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial, Lancet Oncol, vol.17, pp.1590-1598, 2016. ,
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial, Lancet Oncol, vol.18, pp.312-322, 2017. ,
Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study, Lancet Oncol, vol.18, pp.212-220, 2017. ,
Pembrolizumab as second-line therapy for advanced urothelial carcinoma, N Engl J Med, vol.376, pp.1015-1026, 2017. ,
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (keynote-052): a multicentre, single-arm, phase 2 study, Lancet Oncol, vol.18, pp.1483-1492, 2017. ,
Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscleinvasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, Phase II study, J Clin Oncol, vol.36, pp.3353-3360, 2018. ,
Molecular and biochemical aspects of the PD-1 checkpoint pathway, N Engl J Med, vol.375, pp.1767-1778, 2016. ,
Immunotherapy in genitourinary malignancies, J Hematol Oncol, vol.10, p.95, 2017. ,
Mutational landscape and sensitivity to immune checkpoint blockers, Clin Cancer Res, vol.22, pp.4309-4321, 2016. ,
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: an exploratory multi-omic analysis, PLoS Med, vol.14, p.1002309, 2017. ,
Primary, adaptive, and acquired resistance to cancer immunotherapy, Cell, vol.168, pp.707-723, 2017. ,
,
Strategies for predicting response to checkpoint inhibitors, Curr Hematol Malig Rep, vol.13, pp.383-395, 2018. ,
Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance, Exp Mol Med, vol.50, p.109, 2018. ,
The cancer Immunogram as a framework for personalized immunotherapy in urothelial cancer, Eur Urol, vol.75, pp.435-444, 2019. ,
Biomarkers for checkpoint inhibition, Am Soc Clin Oncol Educ Book, vol.37, pp.205-209, 2017. ,
Predicting response to intravesical bacillus Calmette-Guerin Immunotherapy: are we there yet? a systematic review, Eur Urol, vol.73, pp.738-748, 2018. ,
URL : https://hal.archives-ouvertes.fr/pasteur-01659421
EORTC nomograms and risk groups for predicting recurrence, progression, and diseasespecific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Guerin, Eur Urol, vol.69, pp.60-69, 2016. ,
Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model, J Urol, vol.182, pp.2195-2203, 2009. ,
Validation of the ezrin, CK20, and Ki-67 as potential predictive markers for BCG instillation therapy of non-muscle-invasive bladder cancer, Urol Oncol, vol.35, pp.532-531, 2017. ,
The role of fluorescence in situ hybridization to predict patient response to intravesical Bacillus Calmette-Guerin therapy for bladder cancer: a diagnostic meta-analysis and systematic review, Medicine (Baltimore), vol.97, p.12227, 2018. ,
Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guerin therapy for bladder cancer: results of a prospective trial, J Urol, vol.187, pp.862-867, 2012. ,
Novel fluorescence in situ hybridization-based definition of bacille Calmette-Guerin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies, BJU Int, vol.117, pp.754-760, 2016. ,
Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with bacillus Calmette-Guerin therapy for intermediateand high-risk non-muscleinvasive bladder cancer, Medical Oncology, vol.34, p.172, 2017. ,
Interest of next-generation sequencing in BCG-treated high-risk bladder cancer, Prog Urol, vol.28, pp.344-350, 2018. ,
Genomic characterization of high-risk non-muscle invasive bladder cancer, Oncotarget, vol.7, pp.75176-75184, 2016. ,
Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets, Eur Urol, vol.72, pp.952-959, 2017. ,
Next-generation sequencing of urine specimens: a novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guerin, Cancer Cytopathol, vol.125, pp.416-426, 2017. ,
Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guerin response in patients with T1G3 high-risk bladder tumours, Eur Urol, vol.60, pp.131-140, 2011. ,
Myopodin methylation is associated with clinical outcome in patients with T1G3 bladder cancer, J Urol, vol.184, pp.1507-1513, 2010. ,
Polyamine-modulated factor-1 methylation predicts bacillus Calmette-Guerin response in patients with high-grade non-muscleinvasive bladder carcinoma, Eur Urol, vol.63, pp.364-370, 2013. ,
Methylation status as a predictor of intravesical bacillus Calmette-Guerin (BCG) immunotherapy response of high grade non-muscle invasive bladder tumor, Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, vol.161, pp.210-216, 2017. ,
Effect of human leukocyte antigen class I expression of tumor cells on outcome of intravesical instillation of bacillus Calmette-Guerin immunotherapy for bladder cancer, Clin Cancer Res, vol.12, pp.4641-4644, 2006. ,
Efficacy of bacille Calmette-Guerin immunotherapy predicted by expression of antigen-presenting molecules and chemokines, Urology, vol.74, pp.944-950, 2009. ,
Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with bacillus Calmette-Guerin, Oncotarget, vol.9, pp.34066-34078, 2018. ,
PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression, Cancer, vol.109, pp.1499-1505, 2007. ,
Conventional and PD-L1-expressing regulatory T cells are enriched during BCG therapy and may limit its efficacy, Eur Urol, vol.74, pp.540-544, 2018. ,
Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer, Urology, vol.57, pp.617-621, 2001. ,
Predicting response to bacillus Calmette-Guerin (BCG) in patients with carcinoma in situ of the bladder, Urol Oncol, vol.32, p.30, 2014. ,
Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer, Cancer Immunol Immunother, vol.66, pp.427-440, 2017. ,
High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin therapy: a long-term survival analysis, Oncoimmunology, vol.6, p.1265719, 2017. ,
Urinary cytokine profile to predict response to intravesical BCG with or without HS-410 therapy in patients with non-muscle invasive bladder cancer, Cancer Epidemiol Biomarkers Prev, vol.28, pp.1036-1044, 2019. ,
Cytokine panel for response to intravesical therapy (CyPRIT): nomogram of changes in urinary cytokine levels predicts patient response to bacillus Calmette-Guerin, Eur Urol, vol.69, pp.197-200, 2016. ,
Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer, Urol Oncol, vol.34, pp.483-417, 2016. ,
Tumor mutational load predicts survival after immunotherapy across multiple cancer types, Nat Genet, vol.51, pp.202-206, 2019. ,
Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma, Cell, vol.165, pp.35-44, 2016. ,
TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells, Nature, vol.554, pp.544-548, 2018. ,
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade, Science, vol.351, pp.1463-1469, 2016. ,
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy, Science, vol.359, pp.582-587, 2018. ,
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma, Nat Med, vol.24, pp.1545-1549, 2018. ,
PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, vol.515, pp.568-571, 2014. ,
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy, Clin Cancer Res, vol.20, pp.5064-5074, 2014. ,
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, vol.515, pp.563-567, 2014. ,
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma, N Engl J Med, vol.373, pp.23-34, 2015. ,
Pembrolizumab for the treatment of non-small-cell lung cancer, N Engl J Med, vol.372, pp.2018-2028, 2015. ,
A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor, PLoS One, vol.13, p.208422, 2018. ,
Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab, Clin Cancer Res, vol.22, pp.5487-5496, 2016. ,
High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy, Nat Med, vol.24, pp.144-153, 2018. ,
Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab, Clin Cancer Res, vol.24, pp.6212-6222, 2018. ,
Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study, Ann Oncol, vol.28, pp.1996-2001, 2017. ,
Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients, Neoplasia, vol.19, pp.848-855, 2017. ,
The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy, Cancer Cell, vol.33, pp.570-580, 2018. ,
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients, Science, vol.359, pp.97-103, 2018. ,
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients, Science, vol.359, pp.104-108, 2018. ,
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors, Science, vol.359, pp.91-97, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02126484
Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy, Br J Cancer, vol.116, pp.1141-1147, 2017. ,
Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC, Cancer Immunol Res, vol.5, pp.417-424, 2017. ,
Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab, Clin Cancer Res, vol.24, pp.4960-4967, 2018. ,
Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer, Cancer Discov, vol.7, pp.264-276, 2017. ,
Mutations associated with acquired resistance to PD-1 blockade in melanoma, N Engl J Med, vol.375, pp.819-829, 2016. ,
Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes, Nat Biotechnol, vol.33, pp.1152-1158, 2015. ,
Resistance to checkpoint blockade therapy through inactivation of antigen presentation, Nat Commun, vol.8, p.1136, 2017. ,
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints, Nat Commun, vol.7, p.10501, 2016. ,
The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints, Cancer Discov, vol.5, pp.43-51, 2015. ,
Molecular drivers of the non-T-cell-Inflamed tumor microenvironment in urothelial bladder cancer, Cancer Immunol Res, vol.4, pp.563-568, 2016. ,
Loss of PTEN promotes resistance to T cell-mediated immunotherapy, Cancer Discov, vol.6, pp.202-216, 2016. ,
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response, Nat Med, vol.24, pp.1550-1558, 2018. ,
Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment, Proc Natl Acad Sci U S A, vol.115, pp.4041-4050, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01791995
CD73: a potential biomarker for anti-PD-1 therapy, Oncoimmunology, vol.4, p.1046675, 2015. ,
Angiopoietin-2 as a biomarker and target for immune checkpoint therapy, Cancer Immunol Res, vol.5, pp.17-28, 2017. ,
An Immunogram for the cancer-immunity cycle: towards personalized immunotherapy of lung cancer, J Thorac Oncol, vol.12, pp.791-803, 2017. ,
, CANCER IMMUNOLOGY. The 'cancer immunogram'. Science, vol.352, pp.658-660, 2016.
Signatures of mutational processes in human cancer, Nature, vol.500, pp.415-421, 2013. ,
Mutational heterogeneity in cancer and the search for new cancer-associated genes, Nature, vol.499, pp.214-218, 2013. ,
The Cancer Genome Atlas expression subtypes stratify response to checkpoint inhibition in advanced urothelial cancer and identify a subset of patients with high survival probability, Eur Urol, vol.75, pp.961-964, 2019. ,
Interferon gamma messenger RNA signature in tumor biopsies predicts outcomes in patients with non-small cell lung carcinoma or urothelial cancer treated with durvalumab, Clin Cancer Res, vol.24, pp.3857-3866, 2018. ,
EMT-and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer, Nat Commun, vol.9, p.3503, 2018. ,
,
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients, BMC Cancer, vol.16, p.744, 2016. ,
Neoantigen landscape dynamics during human melanoma-T cell interactions, Nature, vol.536, pp.91-95, 2016. ,
Tumor and microenvironment evolution during immunotherapy with nivolumab, Cell, vol.171, pp.934-949, 2017. ,
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response, Nature, vol.545, pp.60-65, 2017. ,
Non-conventional inhibitory CD4(+)Foxp3(-)PD-1(hi) T cells as a biomarker of immune checkpoint blockade activity, Cancer Cell, vol.33, pp.1017-1032, 2018. ,
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma, Nat Med, vol.25, pp.454-461, 2019. ,
Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade, Cancer Discov, vol.6, pp.827-837, 2016. ,
Intra-tumour heterogeneity: a looking glass for cancer?, Nat Rev Cancer, vol.12, pp.323-334, 2012. ,
Cell-free nucleic acids as biomarkers in cancer patients, Nat Rev Cancer, vol.11, pp.426-437, 2011. ,
Liquid biopsies, what we do not know (yet), Cancer Cell, vol.31, pp.172-179, 2017. ,
Integrating liquid biopsies into the management of cancer, Nat Rev Clin Oncol, vol.14, pp.531-548, 2017. ,
Biomarkers for clinical benefit of immune checkpoint inhibitor treatment-a review from the melanoma perspective and beyond, Front Immunol, vol.9, p.1474, 2018. ,
Biomarkers for immune checkpoint inhibitors in melanoma, Front Oncol, vol.8, p.270, 2018. ,
Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy, Proc Natl Acad Sci U S A, vol.115, pp.2467-2472, 2018. ,
High expression of carcinoembryonic antigen and telomerase reverse transcriptase in circulating tumor cells is associated with poor clinical response to the immune checkpoint inhibitor nivolumab, Oncol Lett, vol.15, pp.3061-3067, 2018. ,
Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor-based immunotherapy, Clin Cancer Res, vol.23, pp.5729-5736, 2017. ,
Blood predictive biomarkers for nivolumab in advanced melanoma, Acta Derm Venereol, vol.98, pp.406-410, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-02099448
Baseline neutrophil to lymphocyte ratio combined with serum lactate dehydrogenase level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population, Br J Dermatol, vol.179, pp.213-215, 2018. ,
Neutrophil-to-Lymphocyte ratio (NLR) and platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab, Lung Cancer, vol.111, pp.176-181, 2017. ,
Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy, J Immunother Cancer, vol.5, p.82, 2017. ,
Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer, Lung Cancer, vol.106, pp.1-7, 2017. ,
Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients, Proc Natl Acad Sci, vol.114, pp.4993-4998, 2017. ,
Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma, Int Immunol, vol.30, pp.13-22, 2018. ,
Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients, Oncoimmunology, vol.5, p.1248327, 2016. ,
Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients, J Immunother Cancer, vol.6, p.18, 2018. ,
Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade, Cancer Immunol Res, vol.5, pp.480-492, 2017. ,
Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab, J Transl Med, vol.15, p.244, 2017. ,
Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer, Oncotarget, vol.8, pp.103117-103128, 2017. ,
Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients, Oncoimmunology, vol.6, p.1323618, 2017. ,
A serum protein signature associated with outcome after anti-PD-1 therapy in metastatic melanoma, Cancer Immunol Res, vol.6, pp.79-86, 2018. ,
Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients, Ann Oncol, vol.28, pp.1988-1995, 2017. ,
Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma, Cancer Sci, vol.108, pp.1022-1031, 2017. ,
Prospective validation of a prognostic score for patients in immunotherapy phase I trials: the Gustave Roussy Immune Score (GRIm-Score), Eur J Cancer, vol.84, pp.212-218, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01586940
Active immunotherapy for acute lymphoblastic leukaemia, Lancet, vol.1, pp.697-699, 1969. ,
BCG immunotherapy of malignant melanoma: summary of a seven-year experience, Ann Surg, vol.180, pp.635-643, 1974. ,
Immunological factors which influence response to immunotherapy in malignant melanoma, Surgery, vol.68, pp.158-163, 1970. ,
PA-MSHA induces apoptosis and suppresses metastasis by tumor associated macrophages in bladder cancer cells, Cancer Cell Int, vol.17, p.76, 2017. ,
Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies, Semin Oncol, vol.42, pp.429-435, 2015. ,
Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies, Cancer, vol.110, pp.2614-2627, 2007. ,
Neoantigens in cancer immunotherapy, Science, vol.348, pp.69-74, 2015. ,
PD-1 blockade in tumors with mismatch-repair deficiency, N Engl J Med, vol.372, pp.2509-2520, 2015. ,
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, vol.348, pp.124-128, 2015. ,
Genetic basis for clinical response to CTLA-4 blockade in melanoma, N Engl J Med, vol.371, pp.2189-2199, 2014. ,
Talimogene laherparepvec: first global approval, Drugs, vol.76, pp.147-154, 2016. ,
Evolving immunotherapy strategies in urothelial cancer, Am Soc Clin Oncol Educ Book, pp.284-290, 2015. ,
Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma, Clin Cancer Res, vol.25, pp.967-976, 2018. ,
Optimized targeted sequencing of cell-free plasma DNA from bladder cancer patients, Sci Rep, vol.8, 1917. ,
Targeted DNA and RNA sequencing of paired urothelial and squamous bladder cancers reveals discordant genomic and transcriptomic events and unique therapeutic implications, Eur Urol, vol.74, pp.741-753, 2018. ,
Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile and female gender bias in KDM6A mutation frequency, Cancer Cell, vol.32, pp.701-715, 2017. ,
Comprehensive molecular characterization of muscle-invasive bladder cancer, Cell, vol.171, pp.540-556, 2017. ,
Next-generation sequencingbased molecular characterization of primary urinary bladder adenocarcinoma, Mod Pathol, vol.30, pp.1133-1143, 2017. ,
Molecular and clinical insights into the role and significance of mutated dna repair genes in bladder cancer, Bladder Cancer, vol.4, pp.9-18, 2018. ,
Human papillomavirus infection and bladder cancer risk: a meta-analysis, J Infect Dis, vol.204, pp.217-223, 2011. ,
, ClinicalTrials.gov. Record, vol.02808143, 2018.
, Record No. 02324582, 2018.
Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations, Melanoma Res, vol.28, pp.547-554, 2018. ,
Aligning digital CD8(+) scoring and targeted next-generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early-stage squamous cell lung carcinoma, Histopathology, vol.72, pp.270-284, 2018. ,
PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma, Lung Cancer, vol.89, pp.181-188, 2015. ,
Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung, J Thorac Cardiovasc Surg, vol.155, pp.382-392, 2018. ,
Correlation of PD-L1 expression with tumor mutation burden and gene signatures for prognosis in early-stage squamous cell lung carcinoma, J Thorac Oncol, vol.14, pp.25-26, 2018. ,